- Recommendation ID
- TA316/1
- Question
- NICE supports the manufacturer's ongoing commitment to collect data on the effectiveness of enzalutamide after previous treatment with abiraterone.
- Any explanatory notes
(if applicable) - The use of enzalutamide for treating metastatic hormone-relapsed prostate cancer previously treated with abiraterone is not covered by this guidance.
Source guidance details
- Comes from guidance
- Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
- Number
- TA316
- Date issued
- July 2014
Other details
| Is this a recommendation for the use of a technology only in the context of research? | N/A |
| Is it a recommendation that suggests collection of data or the establishment of a register? | N/A |
| Last Reviewed | 07/10/2014 |